opdivo
Opdivo launched in the UK for skin cancer
July 2, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer
Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …
BMS’ Opdivo accepted to UK early access scheme
June 30, 2015Sales and Marketing BMS, Cancer, NSCLC, eams, keytruda, opdivo
Bristol-Myers Squibb has scored another first with its new-generation oncology therapy Opdivo, which has become the first lung cancer drug …
BMS immunotherapy combination impresses at ASCO
June 1, 2015Research and Development, Sales and Marketing ASCO, BMS, Yervoy, opdivo
Bristol-Myers Squibb has presented data showing that a combination of its immunotherapies Opdivo and Yervoy significantly increases survival in advanced …
BMS’ Opdivo improves lung cancer survival
May 29, 2015Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo
A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
Merck KGaA and Pfizer alliance begins lung cancer study
April 21, 2015Research and Development, Sales and Marketing Merck KGaA, Pfizer, avelumab, keytruda, oncology, opdivo
Merck KGaA and Pfizer have enrolled and treated the first patient in a late-stage study of their anti-PD1 cancer immunotherapy …
BMS’ Opdivo wins US lung cancer race
March 5, 2015Research and Development, Sales and Marketing BMS, Prostvac, biosciences, flexus, lung cancer, oncology, opdivo
The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer …
BMS names operating officer as new chief executive
January 21, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Giovanni Caforio, Lamberto Andreotti, Yervoy, opdivo
Bristol-Myers Squibb’s chief operating officer Giovanni Caforio will be stepping in to Lamberto Andreotti’s shoes as chief executive from May …
BMS Opdivo trial scores early goal
January 14, 2015Research and Development, Sales and Marketing BMS, Merck, cancer nsclc, keytruda, nivolumab, opdivo
A late-stage trial of Bristol-Myers Squibb’s lung cancer drug Opdivo has been stopped early after showing promising results – but …
Lilly, BMS and Merck unite for cancer trials
January 13, 2015Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo
Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …
Pharma industry set for bumper 2015
January 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2015, FDA, bumper, harvoni, opdivo, pharma, sovaldi
Industry analysts predict 2015 will be another year of growth for the pharma, after approvals of new drugs soared to …
Lilly’s lung cancer drug sees FDA approval
December 17, 2014Sales and Marketing BMS, Cancer, FDA, NSCLC, cyramza, docetaxel, lilly, opdivo, ramucirumab
Eli Lilly’s lung cancer drug Cyramza (ramucirumab) has been shown the green light by the US Food and Drug Administration …
Pfizer signs $3 billion cancer deal
November 18, 2014Research and Development, Sales and Marketing Cancer, Merck KGaA, PD-L1, Pfizer, anti-PD-L1, opdivo
Pfizer has signed a multi-billion dollar deal to develop one of Merck KGaA’s investigational drugs, MSB0010718C, an anti-PD-L1 antibody. The …
BMS and Lonza announce expansion plans
October 31, 2014Manufacturing and Production, Sales and Marketing BMS, Lonza, Orencia, manufacturing, opdivo
Bristol-Myers Squibb (BMS) and Lonza are to expand upon an existing manufacturing agreement to meet anticipated demand for commercial biologics. …
BMS, Pharmacyclics and Janssen collaborate on cancer
October 14, 2014Research and Development, Sales and Marketing BMS, Janssen, Pharmacyclics, imbruvica, opdivo
Bristol-Myers Squibb, Pharmacyclics and Janssen are to collaborate on clinical trials combining BMS’s cancer drug Opdivo (nivolumab) with Janssen and …
